Percentage (%) of zero survival cases (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 2.8% | 1.7% | 3.1% | 1.2% | 1.1% | 1.7% |
| All xnmsc 0-24 | 0.3% | 0.4% | 0.3% | 0.4% | 0.9% | 0.0% |
| All xnmsc 25-59 | 0.6% | 0.4% | 0.7% | 0.5% | 0.0% | 0.3% |
| All xnmsc 60-79 | 1.7% | 1.1% | 1.9% | 0.7% | 0.5% | 1.1% |
| All xnmsc 80+ | 7.6% | 4.9% | 8.3% | 3.2% | 3.8% | 4.3% |
| All registrations | 2.0% | 1.2% | 2.2% | 0.8% | 0.7% | 1.1% |
| Haematology | 2.7% | 1.5% | 3.0% | 0.9% | 0.7% | 1.5% |
| Head and Neck | 1.1% | 0.9% | 1.3% | 0.2% | 1.6% | 0.3% |
| Lower GI | 2.5% | 1.5% | 2.7% | 0.9% | 0.9% | 1.4% |
| Upper GI | 3.0% | 2.3% | 3.1% | 1.9% | 1.3% | 2.8% |
| HPB | 5.3% | 2.4% | 6.1% | 1.2% | 0.5% | 1.7% |
| Trachea, Bronchus & Lung | 3.5% | 2.0% | 4.0% | 1.4% | 1.0% | 1.7% |
| Melanoma of skin | 0.3% | 0.2% | 0.3% | 0.0% | 0.3% | 0.4% |
| Breast | 0.8% | 0.6% | 0.9% | 0.4% | 0.7% | 0.4% |
| Cervix | 0.9% | 0.9% | 1.0% | 0.4% | 1.4% | 0.8% |
| Other Female Genitals | 2.2% | 1.8% | 2.3% | 1.2% | 2.2% | 1.4% |
| Prostate | 1.5% | 1.0% | 1.6% | 0.3% | 1.1% | 1.1% |
| Kidney | 2.9% | 1.6% | 3.3% | 0.8% | 0.3% | 1.8% |
| Bladder | 4.1% | 2.0% | 4.6% | 1.4% | 0.0% | 2.1% |
| Brain and CNS | 3.7% | 1.6% | 4.3% | 0.7% | 0.7% | 0.7% |
| Thyroid & other endocrine glands | 1.0% | 0.7% | 1.2% | 0.0% | 0.0% | 1.8% |
| CUP | 16.5% | 10.0% | 18.8% | 6.3% | 5.5% | 9.5% |
| Other invasive cancer | 5.5% | 5.3% | 5.4% | 7.1% | 3.5% | 5.3% |
| Breast in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cervix in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Other tumours | 2.0% | 1.1% | 2.4% | 0.4% | 0.5% | 1.0% |